Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, February 15, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Ami Fadia Reiterated (BIIB) at Strong Buy and Held Target at $325 on, Feb 15th, 2023
Ami Fadia of Needham, Reiterated "Biogen Inc." (BIIB) at Strong Buy and Held Target at $325 on, Feb 15th, 2023.
Ami has made no other calls on BIIB in the last 4 months.
There are 13 other peers that have a rating on BIIB. Out of the 13 peers that are also analyzing BIIB, 4 agree with Ami's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Steve Chesney of "Atlantic Equities" Maintained at Hold with Increased Target to $295 on, Thursday, December 1st, 2022
- Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $247 on, Wednesday, November 30th, 2022
- Carter Gould of "Barclays" Maintained at Hold with Increased Target to $313 on, Wednesday, November 30th, 2022
- Yatin Suneja of "Guggenheim" Maintained at Hold with Increased Target to $270 on, Friday, November 11th, 2022
These are the ratings of the 9 analyists that currently disagree with Ami
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $345 on, Tuesday, January 24th, 2023
- Michael Yee of "Jefferies" Maintained at Strong Buy with Increased Target to $350 on, Wednesday, November 30th, 2022
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $350 on, Tuesday, November 15th, 2022
- Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $315 on, Monday, November 14th, 2022
- Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $325 on, Tuesday, November 1st, 2022
- Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $370 on, Wednesday, October 26th, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $325 on, Wednesday, October 26th, 2022
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $331 on, Wednesday, October 26th, 2022
- Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $310 on, Wednesday, October 26th, 2022
